Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial

(2019) Inge B Halberg et al.   Lancet Diabetes & Endocrinology

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

(2018) T.S. Bailey et al.   DIABETES & METABOLISM

Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial

(2018) Chantal Mathieu et al.   DIABETES OBESITY & METABOLISM

Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials

(2018) Fernanda O. Laranjeira et al.   PLoS One

Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis

(2018) Dalia Dawoud et al.   VALUE IN HEALTH

Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank

(2018) Nicholas J Thomas et al.   Lancet Diabetes & Endocrinology

Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis

(2018) Kirsten Nørgaard et al.   Diabetes Therapy

Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis

(2018) Kirsten Nørgaard et al.   Diabetes Therapy

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial

(2018) John B. Buse et al.   DIABETES OBESITY & METABOLISM

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study

(2018) Halis Kaan Akturk et al.   Diabetes Technology & Therapeutics

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials

(2018) Roy W. Beck et al.   DIABETES CARE

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

(2018) Francesca Porcellati et al.   DIABETES CARE

Introduction: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA)

(2018) T. Pang et al.   DIABETIC MEDICINE

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial

(2018) Martin Tauschmann et al.   LANCET

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

(2017) Wendy Lane et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100 U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials

(2017) William Polonsky et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Development of glucose-responsive ‘smart’ insulin systems

(2017) Nischay K. Rege et al.   Current Opinion in Endocrinology Diabetes and Obesity

Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study

(2017) Lia Bally et al.   Lancet Diabetes & Endocrinology

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

(2016) Tim Heise et al.   CLINICAL PHARMACOKINETICS

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

(2016) Jay S. Skyler et al.   DIABETES

Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up

(2016)   DIABETES CARE

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

(2016) Tim Heise et al.   DIABETES OBESITY & METABOLISM

Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study

(2016) Amin Sharifi et al.   Diabetes Technology & Therapeutics

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)

(2016) I. B. Hirsch et al.   DIABETIC MEDICINE

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

(2015) Richard A. Insel et al.   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

(2015) Philip D. Home et al.   DIABETES CARE

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial

(2015) Bruce W. Bode et al.   DIABETES CARE

Minimizing Hypoglycemia in Diabetes

(2015)   DIABETES CARE

Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial

(2015) M. Davies et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

(2015) T. C. Blevins et al.   DIABETES OBESITY & METABOLISM

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

(2015) T. Heise et al.   DIABETES OBESITY & METABOLISM

Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches

(2015) Ashwini Mallad et al.   Diabetes Technology & Therapeutics

Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management

(2015) H. E. Hopkinson et al.   DIABETIC MEDICINE

Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis

(2015) V. Akbari et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial

(2014) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

(2014) A. Steinstraesser et al.   DIABETES OBESITY & METABOLISM

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

(2014) A. C. Tricco et al.   BMJ-British Medical Journal

Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus

(2013) Hsin-Chieh Yeh et al.   ANNALS OF INTERNAL MEDICINE

Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

(2013) F. Porcellati et al.   DIABETES CARE

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN®Basal-Bolus Type 1): 2-year results of a randomized clinical trial

(2013) B. W. Bode et al.   DIABETIC MEDICINE

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

(2013) Chantal Mathieu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Pathogenesis and Natural History of Type 1 Diabetes

(2013) M. A. Atkinson   Cold Spring Harbor Perspectives in Medicine

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

(2012) I. B. Hirsch et al.   DIABETES CARE

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

(2011) K. I. Birkeland et al.   DIABETES CARE

Non-Inferiority of Insulin Glargine Versus Insulin Detemir on Blood Glucose Variability in Type 1 Diabetes Patients: A Multicenter, Randomized, Crossover Study

(2011) Eric Renard et al.   Diabetes Technology & Therapeutics

Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial

(2011) Arianne C. van Bon et al.   Diabetes Technology & Therapeutics

Comparison of Pharmacokinetic Properties, Physicochemical Stability, and Pump Compatibility of 3 Rapid-Acting Insulin Analogues-Aspart, Lispro, and Glulisine

(2010) Bruce Bode   Endocrine Practice

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

(2009) S. R. Singh et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial

(2009) Simon Heller et al.   CLINICAL THERAPEUTICS

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes

(2009) A. Pfützner et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine

(2009) P. Brunetti et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden

(2008) M. Thunander et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections

(2008) et al.   DIABETIC MEDICINE

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

(2008) P. C. Bartley et al.   DIABETIC MEDICINE

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes

(2008) G.B. Bolli et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES